{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:22:07Z","timestamp":1789525327541,"version":"build-2803163510"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T00:00:00Z","timestamp":1753315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Osteoporosis is a prevalent condition globally, often linked to a significant risk of fractures. Drug-induced osteoporosis (DIOP) is an increasingly recognized adverse effect of various medications, but the sex-specific risks and time-to-onset patterns remain inadequately understood. Addressing these gaps in knowledge is critical to improving patient safety and pharmacovigilance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aimed to explore sex-related differences in DIOP, identify high-risk medications, and assess the onset patterns of osteoporosis-related adverse events by analyzing data from the FDA Adverse Event Reporting System (FAERS) and validating the findings using the Canada Vigilance Adverse Reaction Online Database (Canada Vigilance ADR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed adverse event reports from the FAERS database covering the period from Q1 2004 to Q4 2024. Drugs were standardized using the RxNorm drug terminology system, and adverse events were matched to MedDRA 27.1. Disproportionality analysis was conducted using Reporting Odds Ratio (ROR), Multi-item Gamma Poisson Shrinker (MGPS), and Bayesian Confidence Propagation Neural Network (BCPNN) methods. To validate our findings, we performed external validation using the Canada Vigilance ADR database. Stratified analyses by sex were performed to assess differences in drug-osteoporosis associations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 236,928 osteoporosis-related reports were identified, with 64.6% of the reports coming from females. We identified 68 drugs associated with DIOP, including 15 male-specific and 26 female-specific potential risk drugs. Notable drugs such as tenofovir disoproxil and esomeprazole were linked to both sexes. Drugs like upadacitinib exhibited early-onset failure patterns, while others like tenofovir demonstrated cumulative risk patterns over prolonged use. External validation with the Canada Vigilance ADR confirmed 32 drugs with potential osteoporosis risks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study highlights important sex-specific differences in the risk of drug-induced osteoporosis and underscores the need for targeted pharmacovigilance strategies. The findings contribute to a more personalized approach to drug safety, promoting more informed decision-making regarding medication use in osteoporosis-prone populations.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpubh.2025.1630412","type":"journal-article","created":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:19Z","timestamp":1753335199000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Sex differences in drug-induced osteoporosis: a pharmacovigilance study based on the FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"Lu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjia","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bangguo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11914-025-00909-2","article-title":"Sequential and long-term therapy for osteoporosis","volume":"23","author":"Mcclung","year":"2025","journal-title":"Curr Osteoporos Rep"},{"key":"B2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1093\/bmb\/ldaa005","article-title":"The epidemiology of osteoporosis","volume":"133","author":"Clynes","year":"2020","journal-title":"Br Med Bull"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102930","DOI":"10.5312\/wjo.v16.i3.102930","article-title":"Osteosarcopenia and geriatric hip fractures: current concepts","volume":"16","author":"Tosounidis","year":"2025","journal-title":"World J Orthop"},{"key":"B4","doi-asserted-by":"publisher","first-page":"127446","DOI":"10.1016\/j.jtemb.2024.127446","article-title":"Drug-induced osteoporosis and mechanisms of bone tissue regeneration through trace elements","volume":"84","author":"Costa","year":"2024","journal-title":"J Trace Elem Med Biol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.3390\/ijms24065814","article-title":"Hormone-related and drug-induced osteoporosis: a cellular and molecular overview","volume":"24","author":"Wang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e26153","DOI":"10.1097\/MD.0000000000026153","article-title":"Sex-related differences in bone metabolism in osteoporosis observational study","volume":"100","author":"Choi","year":"2021","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41413-023-00306-4","article-title":"Insights and implications of sexual dimorphism in osteoporosis","volume":"12","author":"Zhang","year":"2024","journal-title":"Bone Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1159\/000543519.","article-title":"A real-world pharmacovigilance analysis for demethylation drug: findings from the FDA adverse event reporting database","author":"Chen","year":"2025","journal-title":"Oncology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B10","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"Dumouchel","year":"1999","journal-title":"Am Stat"},{"key":"B11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1007\/s00228-019-02743-9","article-title":"Drug-induced osteoporosis\/osteomalacia: analysis in the French and Spanish pharmacovigilance databases","volume":"75","author":"Dardonville","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13018-019-1226-6","article-title":"Mortality after osteoporotic hip fracture: incidence, trends, and associated factors","volume":"14","author":"Guzon-Illescas","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.11622\/smedj.2021036","article-title":"Menopausal osteoporosis: screening, prevention and treatment","volume":"62","author":"Yong","year":"2021","journal-title":"Singapore Med J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"101757","DOI":"10.1016\/j.berh.2022.101757","article-title":"Osteoporosis and fractures in rheumatoid arthritis - risk factors","volume":"36","author":"Wysham","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00223-022-00946-4","article-title":"Osteoporosis and HIV infection","volume":"110","author":"Biver","year":"2022","journal-title":"Calcif Tissue Int"},{"key":"B17","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.urology.2004.03.036","article-title":"Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy","volume":"64","author":"Conde","year":"2004","journal-title":"Urology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.7189\/jogh.15.04009","article-title":"Prevalence of osteoporosis and associated factors among Chinese adults: a systematic review and modelling study","volume":"15","author":"Liu","year":"2025","journal-title":"J Glob Health"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e230116","DOI":"10.1530\/JOE-23-0116","article-title":"Postmenopausal osteoporosis coexisting with sarcopenia: the role and mechanisms of estrogen","volume":"259","author":"Lu","year":"2023","journal-title":"J Endocrinol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101551","DOI":"10.1016\/j.beem.2021.101551","article-title":"Menopausal hormone therapy for the management of osteoporosis","volume":"35","author":"Gosset","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"12139","DOI":"10.3390\/ijms252212139","article-title":"Primary osteoporosis induced by androgen and estrogen deficiency: the molecular and cellular perspective on pathophysiological mechanisms and treatments","volume":"25","author":"Hsu","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/s41443-021-00465-0","article-title":"Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey","volume":"34","author":"Efimenko","year":"2022","journal-title":"Int J Impot Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2181953","DOI":"10.1080\/13685538.2023.2181953","article-title":"Subcutaneous testosterone pellet therapy for reversal of male osteoporosis: a review and case report","volume":"26","author":"Dorr","year":"2023","journal-title":"Aging Male"},{"key":"B24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.3389\/fphar.2017.00632","article-title":"Improvement of bone physiology and life quality due to association of risedronate and anastrozole","volume":"8","author":"Monda","year":"2017","journal-title":"Front Pharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/GCO.0b013e32831da80e","article-title":"Aromatase inhibitors and bone health","volume":"21","author":"Bundred","year":"2009","journal-title":"Curr Opin Obstet Gynecol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e2444488","DOI":"10.1001\/jamanetworkopen.2024.44488","article-title":"Gabapentinoids and risk of hip fracture","volume":"7","author":"Leung","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5122(96)01015-8","article-title":"Estrogen and bone metabolism","author":"V\u00e4\u00e4n\u00e4nen","year":"1996","journal-title":"Maturitas"},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11657-022-01090-0","article-title":"Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency","volume":"17","author":"Lee","year":"2022","journal-title":"Arch Osteoporos"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2018.11.001","article-title":"Systemic lupus erythematosus: diagnosis and clinical management","volume":"96","author":"Fava","year":"2019","journal-title":"J Autoimmun"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1154927","DOI":"10.3389\/fendo.2023.1154927","article-title":"Low BMI, blood calcium and vitamin D, kyphosis time, and outdoor activity time are independent risk factors for osteoporosis in postmenopausal women","volume":"14","author":"Tang","year":"2023","journal-title":"Front Endocrinol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e1280","DOI":"10.1210\/clinem\/dgad654","article-title":"Time to benefit of surgery vs. targeted medical therapy for patients with primary aldosteronism: a meta-analysis","volume":"109","author":"Samnani","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1748-5908-6-77","article-title":"Evaluation of a clinical decision support tool for osteoporosis disease management: protocol for an interrupted time series design","volume":"6","author":"Kastner","year":"2011","journal-title":"Implement Sci"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1630412\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T05:33:20Z","timestamp":1753335200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2025.1630412\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,24]]},"references-count":32,"alternative-id":["10.3389\/fpubh.2025.1630412"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2025.1630412","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,24]]},"article-number":"1630412"}}